News & Events

Corporate Presentation
News Releases
Net revenue for ELZONRIS ® was $13.3 million for the third quarter New patient starts estimated to have increased greater than 20% from last quarter Conference call and live webcast scheduled for tomorrow, Friday November 8 th , at 8:00 AM ET NEW YORK , Nov.

Additional Formats

NEW YORK , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp; SL-401), a novel targeted therapeutic

Additional Formats

NEW YORK , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company will host a conference call and webcast on Friday,

Additional Formats

NEW YORK , Oct. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS ® (tagraxofusp) clinical data from the pivotal trial

Additional Formats

NEW YORK , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, presented updated clinical data on the felezonexor (SL-801) Phase 1 trial in

Additional Formats

Upcoming Events
More events are coming soon.